In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

The importance and role of the estrogen receptor (ER) pathway has been well-documented
in both breast cancer (BC) development and progression. The treatment of choice in women …

Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination with
endocrine therapy, and they significantly increase the progression-free survival of patients …

Simple Summary The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6
inhibitors (palbociclib, ribociclib, abemaciclib) to endocrine therapy have remarkably …

Purpose: The activating mutation AKT1 E17K occurs in approximately 7% of estrogen
receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in …

The 17q23 amplicon is associated with poor outcome in ER+ breast cancers, but the causal
genes to endocrine resistance in this amplicon are unclear. Here, we interrogate …

Background Invasive lobular breast carcinoma (ILC) is a histological subtype of breast
cancer that is characterized by loss of E-cadherin and high expression of estrogen receptor …

Abnormal activation of the cyclin-dependent kinases (CDKs), which result in aberrant cell
proliferation, is one of the inherent characteristics of tumor. Thus targeting the activity of …

The genomics-based molecular classifications aim at identifying more homogeneous
classes than immunohistochemistry, associated with a more uniform clinical outcome. We …